Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone774-233-7300
Debt
Current Ratio4.19
Quick Ratio4.19
Price-To-Earnings
Sales & Book Value
Annual Sales$80,000.00
Price / Sales159.22
Price / Cash FlowN/A
Price / Book2.88
Profitability
Net Income$-11,910,000.00
Net MarginsN/A
Return on Assets-138.88%
Miscellaneous
Employees5
OptionableNot Optionable
Biostage (OTCMKTS:BSTG) Frequently Asked Questions
What is Biostage's stock symbol?
Biostage trades on the OTCMKTS under the ticker symbol "BSTG."
How were Biostage's earnings last quarter?
Biostage Inc (OTCMKTS:BSTG) announced its earnings results on Thursday, November, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.28. View Biostage's Earnings History.
When is Biostage's next earnings date?
Has Biostage been receiving favorable news coverage?
Press coverage about BSTG stock has trended negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biostage earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near future.
Who are some of Biostage's key competitors?
Some companies that are related to Biostage include Pro-Dex (PDEX), Obalon Therapeutics (OBLN), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Nephros (NEPH), Restoration Robotics (HAIR), Titan Medical (TMDI), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Dynatronics (DYNT), DarioHealth (DRIO), Lianluo Smart (LLIT), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP) and Invivo Therapeutics (NVIV).
Who are Biostage's key executives?
Biostage's management team includes the folowing people:
- Mr. James J. McGorry, CEO & Director (Age 62)
- Mr. Thomas W. McNaughton, CFO & Sec. (Age 58)
- Yu Hong, Pres (Age 46)
- Ms. Ginger A. Abraham-Freel, Director of Quality & Operations
- Dr. William L. Fodor Ph.D., Chief Scientific Officer
How do I buy shares of Biostage?
Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biostage's stock price today?
One share of BSTG stock can currently be purchased for approximately $2.2465.
How big of a company is Biostage?
Biostage has a market capitalization of $12.70 million and generates $80,000.00 in revenue each year. Biostage employs 5 workers across the globe.
What is Biostage's official website?
How can I contact Biostage?
Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]
MarketBeat Community Rating for Biostage (OTCMKTS BSTG)
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe BSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
